ORPHA:54247
Posterior cortical atrophy
Also known as: Benson syndrome · Biparietal Alzheimer disease · PCA
Publications
2,458
Trials
7
Interventional, condition-specific
Researchers
1,200
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare neurologic disease characterized by impairment of higher visual processing skills and other posterior cortical functions without any evidence of ocular abnormalities, relatively intact memory and language in the early stages, and atrophy of posterior brain regions.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018899
- UMLS:C4275079
Additional Mondo synonyms (1)
biparietal Alzheimer disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,458 matched papers (1,800 in last 10 years) Source
- Phenotype characterisedPresent
21 HPO annotations (e.g. Visual hallucination; Abnormal rapid eye movement sleep; Speech apraxia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
7 matched on ClinicalTrials.gov (5 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
21
Associated phenotypes · MONDO:0018899
- Visual hallucination
- Abnormal rapid eye movement sleep
- Speech apraxia
- Oculomotor apraxia
- Anxiety
Showing 5 of 21 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
2,458
2,458 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
2,458 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,800 in the last 10 years · low confidence
Phrase hits: 2,458 · MeSH hits: 0
Who's working on it?
1,200
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Putcha D15 papers · 2026
Frontotemporal Disorders Unit and Massachusetts Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, 149 13th St, Charlestown, Boston, MA, 02129, USA. dputcha@mgh.harvard.edu.
Papers in Europe PMC - 02Dickerson BC14 papers · 2026
Frontotemporal Disorders Unit and Massachusetts Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, 149 13th St, Charlestown, Boston, MA, 02129, USA.
Papers in Europe PMC - 03Crutch S12 papers · 2026
Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Papers in Europe PMC - 04Josephs KA12 papers · 2025
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Papers in Europe PMC - 05Graff-Radford J11 papers · 2026
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Papers in Europe PMC - 06Rabinovici GD11 papers · 2026
Department of Neurology, University of CA - San Francisco, San Francisco, CA, 94143, USA.
Papers in Europe PMC - 07Whitwell JL11 papers · 2026
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Papers in Europe PMC - 08Katsumi Y10 papers · 2026
Frontotemporal Disorders Unit and Massachusetts Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, 149 13th St, Charlestown, Boston, MA, 02129, USA.
Papers in Europe PMC - 09Yong K10 papers · 2025
Department of Neurodegenerative Disease, Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Papers in Europe PMC - 10Machulda MM9 papers · 2025
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
7
interventional trials for this specific condition
7 interventional trials matched this specific condition name; 5 currently recruiting in our sample.
Data as of 11 September 2026
7 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 90.9th percentile).
low confidence · 90.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
7 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT02740634·RECRUITING·Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Not reviewed·Conditions: Atypical Alzheimer's Disease · Logopenic Progressive Aphasia (LPA) · Posterior Cortical Atrophy (PCA) · Alzheimer Disease·Matched via name phrase
- NCT07191327·RECRUITING·Testing Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy
Not reviewed·Conditions: Posterior Cortical Atrophy·Matched via name phrase
- NCT04150198·RECRUITING·MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
Not reviewed·Conditions: Alzheimer Disease, Early Onset · Posterior Cortical Atrophy·Matched via name phrase
- NCT07222605·ENROLLING BY INVITATION·Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Not reviewed·Conditions: Alzheimer Disease · Parkinson Disease · Frontotemporal Dementia · Cortico Basal Degeneration·Matched via name phrase
- NCT07049341·ENROLLING BY INVITATION·Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases
Not reviewed·Conditions: Alzheimer's Disease · Fronto-temporal Dementia · Parkinson Disease (PD) · Cortico Basal Degeneration·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT04715399·RECRUITING·UPenn Observational Research Repository on Neurodegenerative Disease
Not reviewed·Conditions: Frontotemporal Degeneration(FTD) · Primary Progressive Aphasia(PPA) · Familial Frontotemporal Lobar Degeneration (fFTLD) · Amyotrophic Lateral Sclerosis(ALS)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 7 · after dedupe 7 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 7 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (7)
- isrctn·ISRCTN78730935·Recruiting·A study of JNJ-64042056 in participants with preclinical Alzheimer's disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90897064·No longer recruiting·Dopamine and memory consolidation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10524984·No longer recruiting·Laser for Early Age related macular Degeneration
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57388990·No longer recruiting·Florbetapir F18 (18F-AV-45) amyloid positron emission tomography (PET) imaging in focal dementia syndromes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22636071·No longer recruiting·Efficacy of donepezil in the posterior variant of Alzheimer's disease (posterior cortical atrophy) study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN58435532·No longer recruiting·Amyloid imaging in Alzheimer's disease, frontotemporal dementia and healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN80453162·No longer recruiting·The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Posterior cortical atrophy — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Posterior cortical atrophy" OR "Benson syndrome" OR "Biparietal Alzheimer disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Posterior cortical atrophy" OR "Benson syndrome" OR "Biparietal Alzheimer disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 7 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: PCA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (2458) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T00:55:41.194Z
